Related Experiment Video
Updated: Aug 5, 2025

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
Published on: March 29, 2024
Notopterol Ameliorates Hyperuricemia-Induced Cardiac Dysfunction in Mice
Qian Wang1, Dewei Peng1, Bingyu Huang1
1Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430074, China.
Abstract:
Notopterol is a naturally occurring furanocoumarin compound found in the root of Notopterygium incisum. Hyperuricemia involves the activation of chronic inflammation and leads to cardiac damage. Whether notopterol has cardioprotective potential in hyperuricemia mice remains elusive. The hyperuricemic mouse model was constructed by administration of potassium oxonate and adenine every other day for six weeks. Notopterol (20 mg/kg) and allopurinol (10 mg/kg) were given daily as treatment, respectively. The results showed that hyperuricemia dampened heart function and reduced exercise capacity. Notopterol treatment improved exercise capacity and alleviated cardiac dysfunction in hyperuricemic mice. P2X7R and pyroptosis signals were activated both in hyperuricemic mice and in uric acid-stimulated H9c2 cells. Additionally, it was verified that inhibition of P2X7R alleviated pyroptosis and inflammatory signals in uric acid-treated H9c2 cells. Notopterol administration significantly suppressed expression levels of pyroptosis associated proteins and P2X7R in vivo and in vitro. P2X7R overexpression abolished the inhibition effect of notopterol on pyroptosis. Collectively, our findings suggested that P2X7R played a critical role in uric acid-induced NLRP3 inflammatory signals. Notopterol inhibited pyroptosis via inhibiting the P2X7R/NLRP3 signaling pathway under uric acid stimulation. Notopterol might represent a potential therapeutic strategy against pyroptosis and improve cardiac function in hyperuricemic mice.
Insights
Notopterol improved heart function and exercise capacity in hyperuricemia mice by inhibiting P2X7R/NLRP3 signaling, reducing cell death (pyroptosis). This suggests notopterol as a potential therapy for hyperuricemia-induced cardiac damage.
Area of Science:
- Pharmacology
- Cardiovascular Biology
- Molecular Medicine
Background:
- Hyperuricemia causes chronic inflammation and cardiac damage.
- The cardioprotective effects of notopterol in hyperuricemia are unknown.
- P2X7R and pyroptosis are implicated in hyperuricemia-related inflammation.
Purpose of the Study:
- To investigate the cardioprotective potential of notopterol in a hyperuricemia mouse model.
- To elucidate the underlying molecular mechanisms involving P2X7R and pyroptosis.
Main Methods:
- Hyperuricemia induced in mice using potassium oxonate and adenine.
- Treatment with notopterol (20 mg/kg) or allopurinol (10 mg/kg).
- Assessment of cardiac function, exercise capacity, and molecular markers (P2X7R, pyroptosis proteins) in vivo and in vitro (H9c2 cells).
Main Results:
- Hyperuricemia impaired cardiac function and exercise capacity.
- Notopterol treatment improved exercise capacity and alleviated cardiac dysfunction.
- Notopterol suppressed P2X7R and pyroptosis signaling pathways in vivo and in vitro.
- Inhibition of P2X7R by notopterol was crucial for its anti-pyroptosis effect.
Conclusions:
- Notopterol demonstrates cardioprotective effects in hyperuricemia by inhibiting the P2X7R/NLRP3 signaling pathway.
- Notopterol mitigates uric acid-induced pyroptosis and inflammation.
- Notopterol is a potential therapeutic candidate for managing hyperuricemia-associated cardiac dysfunction.

